Biased for Benefit: Stimulating the world’s most popular drug targets with more nuance
Biology

Biased for Benefit: Stimulating the world’s most popular drug targets with more nuance

From Nature Medicine, June 2017 (Image: Nick Page via Flickr) In September 2012, a small biotech startup named Trevena unveiled preclinical trial results for its front-running compound, TRV027. The fledgling Philadelphia-based company had been going strong since its founding five years earlier, raising $24 million from investors in 2008 and securing a position in BusinessWeek’s … Continue reading